Kalaris Therapeutics, Inc. (KLRS) SEC Filings — 2025
17 SEC filings for Kalaris Therapeutics, Inc. (KLRS) in 2025.
Filings
- Kalaris Therapeutics, Inc. 8-K Filing — 8-K · Dec 18, 2025
- Kalaris Therapeutics, Inc. 8-K Filing — 8-K · Dec 17, 2025
- Kalaris Narrows Losses Post-Merger, Cash Position Strengthens — 10-Q · Nov 12, 2025
- Kalaris Therapeutics Board Changes and Executive Compensation — 8-K · Nov 3, 2025
- Kalaris Therapeutics Files 8-K on Financials — 8-K · Aug 13, 2025
- Kalaris' Losses Mount Post-AlloVir Merger, Cash Position Improves — 10-Q · Aug 13, 2025
- Kalaris Sets Virtual Annual Meeting, Board Elections on Tap — DEF 14A · Jul 1, 2025
- Kalaris Therapeutics Files 8-K on Shareholder Nominations — 8-K · Jun 20, 2025
- Kalaris Therapeutics Files 8-K on Financials — 8-K · May 14, 2025
- Kalaris Therapeutics Q1 2025 Revenue at $4.96M — 10-Q · May 14, 2025
- Kalaris Therapeutics Adds Biotech Veteran to Board — 8-K · Apr 16, 2025
- Kalaris Therapeutics Appoints New Director, Updates Executive Compensation — 8-K · Apr 4, 2025
- Kalaris Therapeutics Reports Key Corporate Changes — 8-K · Mar 18, 2025
- Allovir, Inc. Files 8-K: Officer Departures, Director Elections — 8-K · Mar 12, 2025
- Allovir, Inc. Files 2024 10-K, Reports Merger with Kalaris — 10-K · Mar 7, 2025
- Allovir, Inc. Files 8-K on Security Holder Rights — 8-K · Jan 15, 2025
- Allovir, Inc. Files 8-K on Security Holder Vote Matters — 8-K · Jan 10, 2025